This Article Full Text Full Text (PDF) All Versions of this Article: 110/11/1413    most recent 01.CIR.0000141729.01918.D4v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teo, K. K. Search for Related Content PubMed PubMed Citation Articles by Teo, K. K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cardiac Arrest Related Collections Primary prevention Other Treatment Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2004;110:1413-1417.)
© 2004 American Heart Association, Inc.

Original Articles

Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction

Koon K. Teo, MB PhD; L. Brent Mitchell, MD; Janice Pogue, MSc; Jackie Bosch, MSc; Gilles Dagenais, MD; Salim Yusuf, FRCP DPhil, on behalf of the HOPE Investigators

From the Population Health Research Institute (K.K.T., J.P., J.B., S.Y.), McMaster University, Hamilton, Ontario, Canada; Libin Cardiovascular Institute of Alberta (L.B.M.), University of Calgary, Calgary, Alberta, Canada; and Institut universitaire de cardiologie et de pneumologie (G.D.), Hopital Laval, Ste Foy, Quebec, Canada.

Correspondence to Dr Koon K. Teo, Room 3U4, McMaster University Medical Centre, 1200 Main St W, Hamilton, Ontario, Canada L8N 3Z5. E-mail teok{at}mcmaster.ca

Received May 3, 2004; revision received July 7, 2004; accepted July 14, 2004.

Background— ACE inhibitor therapy reduces the risk of cardiovascular death, myocardial infarction, stroke, hospitalization for heart failure, and need for revascularization in high-risk patients with clinical heart failure, overt left ventricular systolic dysfunction, or vascular disease. In patients with clinical heart failure or overt left ventricular systolic dysfunction, ACE inhibitor therapy also reduces the risk of sudden or arrhythmia-related cardiac death. The objective of this study was to assess the effect of the ACE inhibitor ramipril on sudden unexpected death or resuscitated cardiac arrest among the 9297 individuals without clinical heart failure or overt left ventricular dysfunction enrolled in the Heart Outcomes Prevention Evaluation (HOPE) trial.

Methods and Results— During the median follow-up of 4.5 years, the composite outcome of unexpected death, documented arrhythmic death, or resuscitated cardiac arrest was reduced by 21% in patients randomized to ramipril therapy compared with those randomized to placebo. There were 155 (3.3%) composite outcome events in patients randomized to ramipril therapy compared with 195 (4.2%) such events in patients randomized to placebo (RR 0.79, 95% CI 0.64 to 0.98, P=0.028). There were trends toward reductions in fatal primary outcome events (unexpected death or documented arrhythmic death; RR 0.81, 95% CI 0.64 to 1.02, P=0.072) and in nonfatal primary outcome events (resuscitated cardiac arrest; RR 0.65, 95% CI 0.38 to 1.13, P=0.127) in the ramipril treatment group.

Conclusions— Ramipril reduces the risk of fatal and nonfatal serious arrhythmic events in high-risk patients without clinical heart failure or overt left ventricular systolic dysfunction.

Key Words: angiotensin • arrhythmia • death, sudden • heart arrest • resuscitation

This article has been cited by other articles:

				V. S. Kasi, H. D. Xiao, L. L. Shang, S. Iravanian, J. Langberg, E. A. Witham, Z. Jiao, C. J. Gallego, K. E. Bernstein, and S. C. Dudley Jr. Cardiac-restricted angiotensin-converting enzyme overexpression causes conduction defects and connexin dysregulation Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H182 - H192. [Abstract] [Full Text] [PDF]

				R. A. Kloner and D. S. Cannom Uncertainty on the Use of Aldosterone Antagonists for Primary Therapy for Sudden Cardiac Death in the Setting of Implanted Devices Circulation, June 12, 2007; 115(23): 2983 - 2989. [Full Text] [PDF]